Aberrant expression of polo-like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long-term survival.

Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: eCollection Cited Medium: Internet ISSN: 1792-1082 (Electronic) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE

Original Publication: [Athens : Spandidos Publications]

Polo-like kinase 4 (PLK4) promotes tumorigenesis and is associated with the prognosis of several solid tumors, while its clinical role in patients with renal cell carcinoma (RCC) remains unidentified. The present study aimed to analyze the association of PLK4 with clinicopathological characteristics and long-term prognosis in patients with RCC. The present study detected PLK4 protein and mRNA expression using immunohistochemical and reverse transcription-quantitative PCR assays in 120 patients with RCC. Disease-free survival (DFS) and overall survival (OS) time were calculated based on a median follow-up duration of 6.9 years (range, 1.2-9.9 years). PLK4 protein expression was elevated in tumor tissues compared with adjacent tissues (P<0.001). Upregulation of PLK4 protein was associated with increased T stage (P=0.023), N stage (P=0.014) and TNM stage (P=0.007). Additionally, elevated tumor PLK4 protein expression exhibited an associating trend (without statistical significance) with reduced DFS rate (P=0.066) and was associated with decreased OS rate (P=0.036). However, univariate Cox's regression analysis indicated that high PLK4 protein expression (compared with low PLK4 protein expression) was associated with reduced OS rate (P=0.040) but not with PFS rate (P=0.070). Following adjustment by multivariate Cox's regression analysis, PLK4 protein expression was associated with neither DFS nor OS rate (both P>0.050). Additionally, PLK4 mRNA expression was further detected in some patients (for which fresh specimens frozen in liquid nitrogen were available) to validate the aforementioned observations, and the expression was elevated in tumor tissues compared with adjacent tissues. Furthermore, increased PLK4 mRNA expression was associated with tumor size ≥7 cm, high TNM stage and reduced DFS rate (all P<0.050). PLK4 possesses a certain clinical utility in monitoring the clinical stage of patients with RCC, while its prognostic value requires further validation.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © Jiang et al.)

J Cancer Res Clin Oncol. 2019 Oct;145(10):2413-2422. (PMID: 31492983)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Front Oncol. 2021 Mar 12;11:587554. (PMID: 33777739)
Am Fam Physician. 2019 Feb 1;99(3):179-184. (PMID: 30702258)
J Thorac Dis. 2018 Apr;10(4):2089-2099. (PMID: 29850112)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
World J Oncol. 2020 Jun;11(3):79-87. (PMID: 32494314)
Cells. 2022 Feb 24;11(5):. (PMID: 35269408)
Prostate. 2022 Jun;82(9):957-969. (PMID: 35333404)
J Cell Biol. 2010 Jan 25;188(2):191-8. (PMID: 20100909)
FEBS Open Bio. 2021 Sep;11(9):2631-2646. (PMID: 34342940)
Int J Oncol. 2019 Feb;54(2):479-490. (PMID: 30570110)
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1001-1006. (PMID: 33342155)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
J Hum Genet. 2019 Oct;64(10):1015-1022. (PMID: 31350524)
Anticancer Res. 2022 Apr;42(4):2185-2191. (PMID: 35347043)
Cancer Res. 2017 Jan 15;77(2):434-447. (PMID: 27872092)
Tumour Biol. 2013 Jun;34(3):1887-94. (PMID: 23494182)
J Cell Biochem. 2022 Mar;123(3):581-600. (PMID: 35014077)
Mol Cancer Res. 2022 Apr 1;20(4):596-606. (PMID: 34933912)
Acta Oncol. 2022 Jan;61(1):22-29. (PMID: 34711121)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820935531. (PMID: 32715931)
Cancer Manag Res. 2018 Aug 28;10:2935-2944. (PMID: 30214288)
Hepatology. 2013 May;57(5):2004-13. (PMID: 23300120)
J Clin Lab Anal. 2020 Apr;34(4):e23152. (PMID: 31876063)
Cell Death Dis. 2019 Jul 29;10(8):570. (PMID: 31358734)
Nat Commun. 2013;4:1775. (PMID: 23653187)
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. (PMID: 30459476)
Neoplasia. 2005 Apr;7(4):312-23. (PMID: 15967108)
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188566. (PMID: 33992724)
World J Oncol. 2021 Oct;12(5):178-182. (PMID: 34804281)
Cancer Cell. 2014 Aug 11;26(2):151-3. (PMID: 25117704)
Mol Cancer Ther. 2021 Apr;20(4):632-640. (PMID: 33402398)
J Biol Chem. 2010 Jan 22;285(4):2807-22. (PMID: 19889641)

Keywords: clinicopathological features; disease-free survival; overall survival; polo-like kinase 4; renal cell carcinoma

Date Created: 20221031 Latest Revision: 20221102

20240829

PMC9606728

10.3892/ol.2022.13547

36311683